Rege Nephro

Human kidneys
#Biotechnology #Clinical stage biotechnology #Drug discovery #Funding #Rege Nephro #Regenerative Medicine

Rege Nephro secures US$10.6m for ADPKD and beyond

Rege Nephro, a Japanese clinical-stage biotechnology company focused on iPS cell-based kidney regenerative medicine and drug discovery, has closed a financing round totalling approximately US$10.6 million. Through the issuance of Japan-Keep It Simple Security (J-KISS) share acquisition rights, proceeds are expected to support commercialisation activities for RN-014, the company’s lead… Read More

#News